$14.74
+28%Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ELTX • NASDAQ
| Elicio Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||
-39.6M | -51.9M | -35.2M | -28.2M | -26.4M | -80.1M | -12.3M | -20M | 632.2K | 307.3K | |
1.1M | 1.2M | 1.2M | 1.1M | 251.5K | 628K | 108.4K | 2K | 460.3K | 463.2K | |
0.0 | 0.0 | 0.0 | 0.0 | 53K | 0.0 | 2K | 0.0 | -118K | -212K | |
2.7M | 1.5M | 1.2M | 579K | 617.8K | 0.0 | 145.1K | 0.0 | 0.0 | 0.0 | |
2.2M | 8.2M | 209K | 4.5M | 667K | 30.8M | 18K | 8.3M | 1.6M | 1.2M | |
-3.4M | 4M | -57K | -150K | 872.4K | 25.8M | 2.7M | 3.1M | 332.6K | -75K | |
-37M | -37.1M | -32.7M | -22.2M | -23.9M | -22.9M | -9.3M | -8M | 1.9M | 1.1M | |
INVESTING ACTIVITIES | ||||||||||
-16K | -87K | -66K | -654K | -525.4K | -41K | -489.1K | (0.0) | -17.6K | -47.7K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -50K | (0.0) | |
0.0 | 3K | 34K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-16K | -84K | -32K | -654K | -525.4K | -41K | -489.1K | (0.0) | -67.6K | -47.7K | |
FINANCING ACTIVITIES | ||||||||||
26.8M | 5.6M | 6.8M | 0.0 | 101.4K | 20.3M | -6.7M | 28.6M | 0.0 | 0.0 | |
9.9M | 19.7M | 10M | 0.0 | 14M | 32.1M | 0.0 | 3.1M | 0.0 | 0.0 | |
(0.0) | (0.0) | -150K | (0.0) | (0.0) | -36K | -375K | (0.0) | (0.0) | (0.0) | |
0.0 | 17M | 21.8M | 82K | 314.9K | 0.0 | 6.7M | 0.0 | -1.2M | -429.2K | |
36.7M | 42.3M | 38.6M | 21.2M | 19.4M | 52.4M | 6.3M | 31.7M | -1.2M | -429.2K | |
CASH FLOW SUMMARY | ||||||||||
40K | 22K | 0.0 | 0.0 | 0.0 | -444K | 0.0 | 0.0 | 0.0 | 0.0 | |
-233K | 5.2M | 5.9M | -1.6M | -5.1M | 29M | -3.5M | 23.5M | 652.8K | 588.2K | |
19.5M | 14.3M | 8.4M | 10M | 15.1M | 5.6M | 10.3M | 2.1M | 1.4M | 816.3K | |
19.3M | 19.5M | 14.3M | 8.4M | 10M | 34.6M | 6.8M | 25.5M | 2.1M | 1.4M | |
-37M | -37.2M | -32.8M | -22.8M | -24.5M | -22.9M | -9.8M | -8M | 1.9M | 1M |
ELTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 29, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | March 12, 2026 | March 12, 2026 | ||
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | March 02, 2026 | March 02, 2026 | ||
S-3 S-3 N/A | February 27, 2026 | February 27, 2026 | ||
S-3 S-3 N/A | November 13, 2025 | November 13, 2025 |
Continue your ELTX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.